LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the Tokyo Stock Exchange’s JASDAQ Market (Code Number: 4875) announced today that they will host virtual one-on-one meetings with institutional investors at the Lytham Partners Fall 2022 Investor Conference. The event will take place virtually from September 28th to 29th, 2022.
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will be available for one-to-one meetings at this conference, and investors may request a one-on-one meeting — a meeting by phone Contact Joe Diaz of Lytham Partners at (602) 889-9660, email at diaz@lythampartners.com or by registering at https://www.lythampartners.com/fall2022invreg/.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad pipeline of novel small molecule therapies for late-stage inflammatory, fibrotic and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead compound, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is ready for Phase 3 for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being investigated in phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) has been evaluated in a phase 2 study in idiopathic pulmonary fibrosis (IPF) and a second phase 2 study in nonalcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded by government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements for the purposes of…
